Dyslipidemia in women with polycystic ovary syndrome
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Dyslipidemia is a very common metabolic abnormality in women with polycystic ovary syndrome (PCOS). Insulin resistance is a key pathophysiology of PCOS, thus dyslipidemia in women with PCOS may be consistent with those found in an insulin resistant state. In recent meta-analysis, triglycerides and low-density lipoprotein (LDL) cholesterol levels were 26 mg/dL and 12 mg/dL higher, and high-density lipoprotein cholesterol concentration was 6 mg/dL lower in women with PCOS than those of controls. Alterations in LDL quality also have been reported in women with PCOS: women with PCOS have an increased proportion of atherogenic small dense LDL or decreased mean LDL particle size. However, in a recent Korean study, non-obese Korean women with PCOS had no significant quantitative or qualitative changes in LDL cholesterol profile. Lipoprotein (a) has been identified as an independent risk factor for coronary heart disease, and its elevation in PCOS patients has been consistently reported in diverse studies including non-obese Korean population. Some studies have investigated apolipoprotein (Apo) A-I and ApoC-I levels in women with PCOS and levels of ApoA-I, which has cardio-protective effects, were significantly lower in women with PCOS than those of controls. ApoC-I is known to increase the postprandial serum lipid level that is common in coronary artery disease patients, and one study reported that such an elevation may be the earliest variation of lipid abnormality in women with PCOS. In conclusion, women with PCOS should receive a complete lipid test, and lifestyle modification, including diet and exercise, is the first line therapy for all women with PCOS and is particularly important for those with dyslipidemia.
Abstract
Dyslipidemia is a very common metabolic abnormality in women with polycystic ovary syndrome (PCOS). Insulin resistance is a key pathophysiology of PCOS, thus dyslipidemia in women with PCOS may be consistent with those found in an insulin resistant state. In recent meta-analysis, triglycerides and low-density lipoprotein (LDL) cholesterol levels were 26 mg/dL and 12 mg/dL higher, and high-density lipoprotein cholesterol concentration was 6 mg/dL lower in women with PCOS than those of controls. Alterations in LDL quality also have been reported in women with PCOS: women with PCOS have an increased proportion of atherogenic small dense LDL or decreased mean LDL particle size. However, in a recent Korean study, non-obese Korean women with PCOS had no significant quantitative or qualitative changes in LDL cholesterol profile. Lipoprotein (a) has been identified as an independent risk factor for coronary heart disease, and its elevation in PCOS patients has been consistently reported in diverse studies including non-obese Korean population. Some studies have investigated apolipoprotein (Apo) A-I and ApoC-I levels in women with PCOS and levels of ApoA-I, which has cardio-protective effects, were significantly lower in women with PCOS than those of controls. ApoC-I is known to increase the postprandial serum lipid level that is common in coronary artery disease patients, and one study reported that such an elevation may be the earliest variation of lipid abnormality in women with PCOS. In conclusion, women with PCOS should receive a complete lipid test, and lifestyle modification, including diet and exercise, is the first line therapy for all women with PCOS and is particularly important for those with dyslipidemia.
참고문헌 (44)
- Knochenhauer ES, "Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States : a prospective study", J Clin Endocrinol Metab, 83, pp.3078~3082 (1998)
- Asuncion M, "A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain", J Clin Endocrinol Metab, 85, pp.2434~2438 (2000)
- Legro RS, "Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome", Am J Med, 111, pp.607~613 (2001)
- Sniderman AD, "Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus", Ann Intern Med, 135, pp.447~459 (2001)
- Barter PJ, "Cholesteryl ester transfer protein : a novel target for raising HDL and inhibiting atherosclerosis", Arterioscler Thromb Vasc Biol, 23, pp.160~167 (2003)
- Brunzell JD, "Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus", Am J Med, 115(Suppl 8A), pp.S24~S28 (2003)
- Taskinen MR, "LDL-cholesterol, HDL-cholesterol or triglycerides: which is the culprit?", Diabetes Res Clin Pract, 61(Suppl 1), pp.S19~S26 (2003)
- Lee H, "The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome", Endocrine, 36, pp.326~332 (2009)
- Wild RA, "Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome", J Clin Endocrinol Metab, 61, pp.946~951 (1985)
- Meirow D, "Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?", Hum Reprod, 11, pp.1848~1853 (1996)
- Robinson S, "Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries", Clin Endocrinol (Oxf), 44, pp.277~284 (1996)
- Diamanti-Kandarakis E, "The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome", J Clin Endocrinol Metab, 83, pp.2699~2705 (1998)
- Talbott E, "Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome : results of a case-control study", J Clin Epidemiol, 51, pp.415~422 (1998)
- Dejager S, "Smaller LDL particle size in women with polycystic ovary syndrome compared to controls", Clin Endocrinol (Oxf), 54, pp.455~462 (2001)
- Orio F, "The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study", J Clin Endocrinol Metab, 89, pp.3696~3701 (2004)
- Yilmaz M, "Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome", Gynecol Endocrinol, 20, pp.258~263 (2005)
- Wild RA, "Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis", Fertil Steril, 95, pp.1073-9.e1~1073-9.e11 (2011)
- Warnick GR, "Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays", Clin Chem, 47, pp.1579~1596 (2001)
- Talbott E, "Coronary heart disease risk factors in women with polycystic ovary syndrome", Arterioscler Thromb Vasc Biol, 15, pp.821~826 (1995)
- Conway GS, "Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome", Clin Endocrinol (Oxf), 37, pp.119~125 (1992)
- Valkenburg O, "A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study", J Clin Endocrinol Metab, 93, pp.470~476 (2008)
- Recabarren SE, "Metabolic profile in sons of women with polycystic ovary syndrome", J Clin Endocrinol Metab, 93, pp.1820~1826 (2008)
- Sam S, "Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome", Proc Natl Acad Sci U S A, 103, pp.7030~7035 (2006)
- Sam S, "Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome", J Clin Endocrinol Metab, 90, pp.4797~4802 (2005)
- Legro RS, "Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome : influence of insulin and genetic factors", Fertil Steril, 72, pp.990~995 (1999)
- Pirwany IR, "Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters", Clin Endocrinol (Oxf), 54, pp.447~453 (2001)
- Berneis K, "Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome", J Clin Endocrinol Metab, 92, pp.186~189 (2007)
- Doi SA, "LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome", Am J Clin Pathol, 129, pp.802~810 (2008)
- Rizzo M, "Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype", Hum Reprod, 24, pp.2286~2292 (2009)
- Phelan N, "Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS", J Clin Endocrinol Metab, 95, pp.3933~3939 (2010)
- Sidhwani S, "PCOS is associated with atherogenic changes in lipoprotein particle number and size independent of body weight", Clin Endocrinol (Oxf) (2011)
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)., "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report", Circulation, 106, pp.3143~3421 (2002)
- Kim JJ, "Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome", Hum Reprod, 28, pp.1354~1360 (2013)
- Groot PH, "Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease", Arterioscler Thromb, 11, pp.653~662 (1991)
- Phillips NR, "Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events", Circulation, 88, pp.2762~2770 (1993)
- Huang S, "Can serum apolipoprotein C-I demonstrate metabolic abnormality early in women with polycystic ovary syndrome?", Fertil Steril, 94, pp.205~210 (2010)
- Emerging Risk Factors Collaboration, "Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality", JAMA, 302, pp.412~423 (2009)
- Erqou S, "Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants", J Am Coll Cardiol, 55, pp.2160~2167 (2010)
- Dube JB, "Lipoprotein(a): more interesting than ever after 50 year", Curr Opin Lipidol, 23, pp.133~140 (2012)
- Berneis K, "Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome", Int J Clin Pract, 63, pp.56~62 (2009)
- Chae SJ, "Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women", Hum Reprod, 23, pp.1924~1931 (2008)
- Wild RA, "Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society", J Clin Endocrinol Metab, 95, pp.2038~2049 (2010)
- Banaszewska B, "Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial", J Clin Endocrinol Metab, 92, pp.456~461 (2007)
- Sathyapalan T, "The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study", J Clin Endocrinol Metab, 94, pp.103~108 (2009)